Add like
Add dislike
Add to saved papers

Spiromesifen and spirotetramat resistance in field populations of Bemisia tabaci Gennadius in Spain.

BACKGROUND: Spiromesifen and spirotetramat are novel insecticides belonging to the chemical class of tetronic and tetramic acid derivatives. Both compounds have proven very effective against field populations of Bemisia tabaci around the world. However, several growers have recently reported control failures in Spain. Therefore, we studied the resistance level to these insecticides in field populations reporting control failures. In addition, we further selected a spiromesifen-resistant strain to study the mechanisms involved and the cross-resistance pattern.

RESULTS: All the new field populations collected were significantly more resistant to spiromesifen than the susceptible population, confirming the presence of resistance. Several populations showing high levels of resistance to spiromesifen (>10 000-fold), exhibited cross-resistance to spirotetramat, but resistance ratios were much lower (130-fold). The spiromesifen laboratory-selected strain was very resistant to spiromesifen (LC50  > 30 000 mg L-1 ) and spirotetramat (LC50  = 368.1 mg L-1 ), but lacks any cross-resistance to other insecticides, thus providing options for resistance management. None of the synergists tested significantly restored the susceptibility of B. tabaci to either spiromesifen or spirotetramat.

CONCLUSION: This is the first report of resistance to spiromesifen and spirotetramat in B. tabaci, and such high levels of resistance have not been reported before in any field collected pest. Our results suggest that enhanced detoxification does not critically contribute to resistance to ketoenols in B. tabaci. The obvious lack of a metabolic resistance mechanism either suggests a target-site resistance mechanism or a metabolic mechanism insensitive to the synergists tested. © 2018 Society of Chemical Industry.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app